Clopidogrel is an established antiplatelet agent with extensive evidence supporting its use across the spectrum of ischaemic heart disease.
Clopidogrel's established role supports ongoing use in ischaemic heart disease; leaves open optimal integration with newer agents.
Clopidogrel is an effective antiplatelet agent that has undergone rigorous assessment in the setting of ischaemic heart disease over the last decade. There is extensive evidence for the use of this drug in patients undergoing percutaneous coronary intervention, in those with stable ischaemic heart disease and also in those with acute coronary syndromes. This article examines the use of clopidogrel in patients with ischaemic heart disease.
No takes yet. Share an insight, caveat, or question.
Walsh et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: